Home/Gilgamesh Pharmaceuticals/Gerard Marek, MD PhD

GM

Gerard Marek, MD PhD

Chief Medical Officer (CMO)

Gilgamesh Pharmaceuticals

Therapeutic Areas

Major Depressive Disorder Anxiety Disorders Opioid Use Disorder Psychiatric Diseases

Gilgamesh Pharmaceuticals Pipeline

Drug	Indication	Phase
NMDAR Antagonist (GM-2505/Bretisilocin)	Major Depressive Disorder	Phase 2
Neuroplastogen (GM-1020)	Major Depressive Disorder	Phase 2a
Safer Ibogaine Analogs	Opioid Use Disorder	Pre-clinical/Research

Leadership Team at Gilgamesh Pharmaceuticals

Jonathan Sporn, MD

Andrew Kruegel, PhD

Co-Founder, CSO

Jorge Quiroz, MD MBA

Chief Development & Strategy Officer (CDSO)

Laszlo Kiss, PhD

Chief Business Officer & Head of Research

View full Gilgamesh Pharmaceuticals profile